White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab
| Autor: | Stuart A. Grossman, Fayez Estephan, Xiaobu Ye, Matthias Holdhoff, Doris D. M. Lin |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty business.industry Systemic chemotherapy Primary central nervous system lymphoma food and beverages medicine.disease White matter changes High dose methotrexate Internal medicine Medicine Methotrexate Rituximab sense organs skin and connective tissue diseases business Neurocognitive medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 36:e14038-e14038 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2018.36.15_suppl.e14038 |
| Popis: | e14038Background: White matter changes (WMC) can develop following systemic chemotherapy and may be associated with neurocognitive decline. High-dose methotrexate (HD-MTX) is the most commonly used... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|